←
Chai Bandlamudi57 posts
Chai Bandlamudi avatar

Chai Bandlamudi

@chaiband

Assistant Member @MSKPathology | Computational Oncology | Translational Biomarker Discovery | Cancer Genomics | Germline Predisposition to Cancer

◷ Joined December 2012▧ 15 Photos and videos
Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

Thrilled to share our recent work in @CellCellPress ✨ We study the extent to which tumor suppressor genes in cancer adhere to Knudson's ‘two-hit’ hypothesis, and their clinical implications. 🧵👇 Also a detailed 🧵 by @EdReznik below: @MSKPathology @MSKCancerCenter

A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in @CellCellPress. With Mark Zucker, Maria Perry, and Chai Bandlamudi cell.com/cell/fulltext/S0092…

Michael Berger avatar
⟳ Chai Bandlamudi retweeted
Michael Berger@MFBerger1·Mar 26

Thanks @Aiims1742 for highlighting-- and to the entire @MSKCancerCenter team for everything it takes to support this program day in and day out

MSK-IMPACT is truly the gift that keeps on giving! Cancer type-specific variation in patterns of driver alterations across 50,000 tumors (!!) cell.com/cancer-cell/fulltex… "One-third of all drivers arose in non-canonical contexts" Congratulations @MFBerger1 @DSolit & team.

Post attachment
Avantika Gupta avatar
⟳ Chai Bandlamudi retweeted
Avantika Gupta@AvanGupta·16 May 2025

So excited to share our latest work with Sarat Chandarlapaty, @antoniomarraMD, Andrea Gazzo @MSKCancerCenter out today in @NatureGenet! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/ nature.com/articles/s41588-0…

Arvind Narayanan avatar
⟳ Chai Bandlamudi retweeted
Arvind Narayanan@random_walker·9 Jan 2025

Something I've observed in academia but I suspect is true in industry as well: as you become more senior, you'll find that you can be much more productive if you spend all your time being a manager and letting junior people do all the real work. But after a few years of this, you're likely to lose your skill at doing the work yourself, the opportunity to practice that skill, and the gratification of doing so that drew you to your chosen profession in the first place. And you'll probably also get worse at being a manager as you lose touch with the actual work. Avoiding managerdom is hard. You have to give up substantial short-term productivity gains. If you're in academia in a tenure track, you risk not getting tenure by being less productive. And personally I find that switching between thinker mode (deep work with no distractions for a whole day) and manager mode (a thousand quick but urgent tasks) to be highly unpleasant. When I'm in thinker mode, it kills me that people have to wait a day (often a lot more) for a 1-minute response from me that could unblock them on what they're stuck on and save them hours of work. When I'm in manager mode, it kills me that I have all these creative ideas sloshing around in my brain that I'm not able to execute on. So it's extremely tempting to perpetually be in just one mode or the other. When you have a team, not managing them is not an option, but being a pure manager is an option. That makes a constant struggle to carve out time for your own work and not give in to the temptation. Note: I think this is only tangentially related to Founder Mode vs Manager Mode. It's much more related to another Paul Graham essay, Maker's Schedule vs Manager's Schedule. And Deep Work by Cal Newport is very relevant.

Maria A Perry avatar
⟳ Chai Bandlamudi retweeted
Maria A Perry@MariaAPerry·9 Jan 2025

So happy to finally share this work! Thank you @AnnaVarghese4 @chaiband @EileenMOReilly @MFBerger1 @nikolausschultz for all of your guidance & insight 🧬 Research Briefing: doi.org/10.1038/s41591-024-0…

Excited to share our latest in @NatureMedicine✨ We present a detailed clinico-genomic landscape of pancreatic adenocarcinomas With important implications for RAS 🎯 therapies Expertly co-led by @AnnaVarghese4 and @MariaAPerry. w/@EileenMOReilly & colleagues @MSKCancerCenter

Post attachment
Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·4 Jan 2025

Paper: nature.com/articles/s41591-0… Data for 2,336 patients with PDAC on cBioPortal: cbioportal.org/study/summary… @MSKPathology @CpcrMsk @MSK_DeptOfMed

Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

Overall, our findings suggest that zygosity of TSG muts matter, and is a poorly recognized biomarker in solid tumors. (Btw, for oncogenes too. Coming soon!) This highlights the importance of inferring and reporting allele-specific copy number in clinical reports. #MSKIMPACT /9

Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

These findings are particularly meaningful given recent work by @FSkoulidis and J.Heymach showing that KEAP1-mutated lung adenocarcinoma pts derived particular clinical benefit from dual ICB compared to PD-L1 inhibitor alone. #PredictiveBiomarker nature.com/articles/s41586-0… /8

Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

KEAP1 stood out as it is also a well-known prognostic biomarker in LUAD. So, we asked if the outcomes to standard of care Tx in LUAD also differed by KEAP1 zygosity. Indeed they did! Only KEAP1 biallelic but not monoallelic patients had shorter PFS. 🙏@AdamJSchoenfeld /7

Post attachment
Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

But, does TSG zygosity matter for patient outcomes? It appears it does. For several TSGs, we find that zygosity is strongly associated with overall survival (OS). These include Class 1 (TP53, PTEN, KEAP1, etc) as well as Class 2 (eg: SMARCA4) genes. /6

Post attachment
Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

We also highlight several ways in which patterns for selection for two-hits can be used to increase focus on TSGs mutated in non-canonical cancers or re-prioritize VUSs (see paper). Thanks to the exceptional contribution and creativity from Sam Gould and @fjsanchezrivera 🙏/5

Chai Bandlamudi avatar
Chai Bandlamudi@chaiband·18 Dec 2024

The most interesting group of TSGs were Class 2 (eg: ATM, ARID1A, etc) which are mutated in 1 in 5 cancers. These genes showed context-specific patterns of selection for biallelic losses, and thus providing a rich substrate for future work in understanding their function. /4